{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T08:53:52Z","timestamp":1758444832108,"version":"3.44.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,20]]},"DOI":"10.7759\/cureus.92806","type":"journal-article","created":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T02:28:48Z","timestamp":1758421728000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Oncological Tolerance of Testosterone Replacement Therapy Over Two Years Among Patients With High-Risk or Very High-Risk Prostate Cancer Undergoing Radiotherapy"],"prefix":"10.7759","author":[{"given":"Kazuyoshi","family":"Shigehara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Shinzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yaegshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/13685530802389628","article-title":"ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males","volume":"12","author":"Wang C","year":"2009","unstructured":"Wang C, Nieschlag E, Swerdloff RS, et al.. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009, 12:5-12. 10.1080\/13685530802389628","journal-title":"Aging Male"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12880","article-title":"Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management","volume":"22","author":"Hisasue S","year":"2015","unstructured":"Hisasue S. Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management. Int J Urol. 2015, 22:1084-95. 10.1111\/iju.12880","journal-title":"Int J Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101301","article-title":"Late-onset hypogonadism: clinical evidence, biological aspects and evolutionary considerations","volume":"67","author":"Jaschke N","year":"2021","unstructured":"Jaschke N, Wang A, Hofbauer LC, Rauner M, Rachner TD. Late-onset hypogonadism: clinical evidence, biological aspects and evolutionary considerations. Ageing Res Rev. 2021, 67:101301. 10.1016\/j.arr.2021.101301","journal-title":"Ageing Res Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15160","article-title":"Summary of the clinical practice manual for late-onset hypogonadism","volume":"30","author":"Ide H","year":"2023","unstructured":"Ide H, Akehi Y, Fukuhara S, et al.. Summary of the clinical practice manual for late-onset hypogonadism. Int J Urol. 2023, 30:422-30. 10.1111\/iju.15160","journal-title":"Int J Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-4683.2012.07.03","article-title":"Role of hormonal therapy for prostate cancer: perspective from Japanese experiences","volume":"1","author":"Namiki M","year":"2012","unstructured":"Namiki M, Ueno S, Kitagawa Y. Role of hormonal therapy for prostate cancer: perspective from Japanese experiences. Transl Androl Urol. 2012, 1:160-72. 10.3978\/j.issn.2223-4683.2012.07.03","journal-title":"Transl Androl Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2020.1731450","article-title":"Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy","volume":"23","author":"Kato Y","year":"2020","unstructured":"Kato Y, Shigehara K, Kawaguchi S, Izumi K, Kadono Y, Mizokami A. Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy. Aging Male. 2020, 23:1210-6. 10.1080\/13685538.2020.1731450","journal-title":"Aging Male"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2018.59.1.18","article-title":"Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer","volume":"59","author":"Nam W","year":"2018","unstructured":"Nam W, Choi SY, Yoo SJ, et al.. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer. Investig Clin Urol. 2018, 59:18-24. 10.4111\/icu.2018.59.1.18","journal-title":"Investig Clin Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen PL","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, et al.. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015, 67:825-36. 10.1016\/j.eururo.2014.07.010","journal-title":"Eur Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/13685538.2011.650246","article-title":"Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010","volume":"15","author":"Gooren LJ","year":"2012","unstructured":"Gooren LJ, Behre HM. Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. Aging Male. 2012, 15:22-7. 10.3109\/13685538.2011.650246","journal-title":"Aging Male"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler A","year":"2009","unstructured":"Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009, 55:310-20. 10.1016\/j.eururo.2008.09.024","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-020-01023-2","article-title":"Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-\/very high-risk prostate cancer: A dosimetric analysis of toxicity","volume":"38","author":"Sakurai T","year":"2020","unstructured":"Sakurai T, Takamatsu S, Shibata S, et al.. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-\/very high-risk prostate cancer: A dosimetric analysis of toxicity. Jpn J Radiol. 2020, 38:1197-208. 10.1007\/s11604-020-01023-2","journal-title":"Jpn J Radiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler JL","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, et al.. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019, 17:479-505. 10.6004\/jnccn.2019.0023","journal-title":"J Natl Compr Canc Netw"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000136269.10161.32","article-title":"Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men","volume":"172","author":"Kaufman JM","year":"2004","unstructured":"Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004, 172:920-2. 10.1097\/01.ju.0000136269.10161.32","journal-title":"J Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01161.x","article-title":"Testosterone replacement therapy following radical prostatectomy","volume":"6","author":"Khera M","year":"2009","unstructured":"Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009, 6:1165-70. 10.1111\/j.1743-6109.2009.01161.x","journal-title":"J Sex Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15042","article-title":"Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy","volume":"126","author":"Ahlering TE","year":"2020","unstructured":"Ahlering TE, My Huynh L, Towe M, et al.. Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy. BJU Int. 2020, 126:91-6. 10.1111\/bju.15042","journal-title":"BJU Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.002","article-title":"Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy","volume":"190","author":"Pastuszak AW","year":"2013","unstructured":"Pastuszak AW, Pearlman AM, Lai WS, et al.. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013, 190:639-44. 10.1016\/j.juro.2013.02.002","journal-title":"J Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22438","article-title":"Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy","volume":"109","author":"Sarosdy MF","year":"2007","unstructured":"Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007, 109:536-41. 10.1002\/cncr.22438","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12668","article-title":"Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer","volume":"114","author":"Balbontin FG","year":"2014","unstructured":"Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014, 114:125-30. 10.1111\/bju.12668","journal-title":"BJU Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.05.084","article-title":"Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer","volume":"194","author":"Pastuszak AW","year":"2015","unstructured":"Pastuszak AW, Khanna A, Badhiwala N, et al.. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015, 194:1271-6. 10.1016\/j.juro.2015.05.084","journal-title":"J Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.180130","article-title":"Testosterone replacement therapy for patients with hypogonadism after high dose-rate brachytherapy for high-risk prostate cancer: a report of six cases and literature review","volume":"38","author":"Kadomoto S","year":"2020","unstructured":"Kadomoto S, Shigehara K, Iwamoto H, Yaegashi H, Izumi K, Kadono Y, Mizokami A. Testosterone replacement therapy for patients with hypogonadism after high dose-rate brachytherapy for high-risk prostate cancer: a report of six cases and literature review. World J Mens Health. 2020, 38:132-6. 10.5534\/wjmh.180130","journal-title":"World J Mens Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12429","article-title":"Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends","volume":"11","author":"Kaplan AL","year":"2014","unstructured":"Kaplan AL, Trinh QD, Sun M, et al.. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med. 2014, 11:1063-70. 10.1111\/jsm.12429","journal-title":"J Sex Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.06.007","article-title":"Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis","volume":"37","author":"Kardoust Parizi M","year":"2019","unstructured":"Kardoust Parizi M, Abufaraj M, Fajkovic H, et al.. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis. Urol Oncol. 2019, 37:637-46. 10.1016\/j.urolonc.2019.06.007","journal-title":"Urol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.04.069","article-title":"Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes","volume":"196","author":"Ory J","year":"2016","unstructured":"Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016, 196:1082-9. 10.1016\/j.juro.2016.04.069","journal-title":"J Urol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.19.2351","article-title":"Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial","volume":"296","author":"Marks LS","year":"2006","unstructured":"Marks LS, Mazer NA, Mostaghel E, et al.. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006, 296:2351-61. 10.1001\/jama.296.19.2351","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.11.084","article-title":"Testosterone therapy in men with untreated prostate cancer","volume":"185","author":"Morgentaler A","year":"2011","unstructured":"Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011, 185:1256-60. 10.1016\/j.juro.2010.11.084","journal-title":"J Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682X.160270","article-title":"Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results","volume":"18","author":"Kacker R","year":"2016","unstructured":"Kacker R, Hult M, San Francisco IF, Conners WP, Rojas PA, Dewolf WC, Morgentaler A. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016, 18:16-20. 10.4103\/1008-682X.160270","journal-title":"Asian J Androl"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.04.008","article-title":"Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer","volume":"38","author":"Lenfant L","year":"2020","unstructured":"Lenfant L, Leon P, Cancel-Tassin G, Audouin M, Staerman F, Roupr\u00eat M, Cussenot O. Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer. Urol Oncol. 2020, 38:661-70. 10.1016\/j.urolonc.2020.04.008","journal-title":"Urol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403024-clinical-oncological-tolerance-of-testosterone-replacement-therapy-over-two-years-among-patients-with-high-risk-or-very-high-risk-prostate-cancer-undergoing-radiotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T02:28:54Z","timestamp":1758421734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403024-clinical-oncological-tolerance-of-testosterone-replacement-therapy-over-two-years-among-patients-with-high-risk-or-very-high-risk-prostate-cancer-undergoing-radiotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.92806","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,20]]}}}